Piperaquine

Piperaquine was developed in the 1960s as a part of the Chinese National Malaria Elimination Programme [42]. Initially used throughout China as a replacement for chloroquine, resistance led to its diminished use as a monotherapy. While the MoA of piperaquine is not completely understood, studies have suggested that it acts by accumulating in the digestive vacuole and inhibiting haem detoxification through the binding of haem-containing species [30, 43]. These days, piperaquine is used as a partner drug with dihydroartemisinin (commonly sold under the trade name Eurartesim®).